Sun Pharma
| Company type | Public |
|---|---|
| |
| ISIN | INE044A01036 |
| Industry | Pharmaceuticals |
| Founded | 1983 |
| Founder | Dilip Shanghvi |
| Headquarters | , India |
Area served | Worldwide |
Key people | Dilip Shanghvi (MD) |
| Products | |
| Revenue | ₹52,578 crore (US$6.2 billion) (2025) |
| ₹15,271 crore (US$1.8 billion) (2025) | |
| ₹11,984 crore (US$1.4 billion) (2025) | |
| Total assets | ₹92,100 crore (US$11 billion) (2025) |
| Total equity | ₹72,485 crore (US$8.6 billion) (2025) |
| Owner | Dilip Shanghvi family (54.48%) |
Number of employees | 41,000+ (2023) |
| Website | sunpharma |
| Footnotes / references Financials as of 31 March 2025. | |
Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.